Meningococcal polysaccharide conjugate vaccine serogroups a, c, w-135 and y

PBAC's latest decision on Meningococcal polysaccharide conjugate vaccine serogroups a, c, w-135 and y: Recommended with restriction (2018). Considered for Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y in infants aged 12 months.

Eligible population

Healthy infants aged 12 months for prevention of invasive meningococcal disease caused by serogroups A, C, W, and Y.

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Immunogenicity (serum bactericidal antibody titre ≥ 1:8)

Pivotal trial size

1,043 patients

Key trials

MenACWY-TT-013, MenACWY-TT-027, MenACWY-TT-039, MenACWY-TT-040, Hib-MenC-TT-016

Comparator

Haemophilus influenzae type B and meningococcal C conjugate vaccine (Hib-MenC; Menitorix)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Similar precedents

• Meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine
  similarity 0.87
• Meningococcal polysaccharide serogroups a, c, w-135 and y conjugate vaccine
  similarity 0.84
• Meningococcal group b vaccine, multicomponent (4cmenb)
  similarity 0.72
• Meningococcal group b vaccine (4cmenb)
  similarity 0.71
• Meningococcal group b vaccine (recombinant, adsorbed)
  similarity 0.70
• Pneumococcal polysaccharide conjugate vaccine, 13-valent
  similarity 0.67